Team GB swimming legend Ellie Simmonds has opened up on the heartbreaking decision she faces on whether or not she should ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Ms Simmonds, 30, has the least impaired version of achondroplasia (the official name for dwarfism) and her life has certainly been one of vast achievement. From winning two golds aged 13 at the ...

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study.

At the core of achondroplasia's pathology lies the hyperactivation of FGFR3, which impairs not only the growth of long bones but also affects cranial, spinal, and vertebral development. The ...

for treating children with achondroplasia. This development marks a significant step for Abbisko as ABSK061 is the first FGFR2/3 inhibitor to enter clinical trials globally, aiming to provide a ...

Discover top medications for 'treating Achondroplasia'? This page compiles essential information on generic and brand-name drugs specifically used for Achondroplasia treatment.Here, you can ...

California-based BioMarin said the US filing for vosoritide in achondroplasia could lead to the first treatment for children with achondroplasia, the most common form of disproportionate short ...

COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Suggested remit: To appraise the clinical and cost effectiveness of Vosoritide within its marketing authorisation for treating achondroplasia in children.

The double-blind placebo-controlled ApproaCH Trial included 84 children with achondroplasia (aged 2-11 years) randomized 2:1 (TransCon CNP:placebo) for 52 weeks, followed by an open-label ...